8-K: Sagimet Biosciences Provides Update on Denifanstat Development Programs

Sagimet Biosciences has released an updated investor presentation highlighting positive Phase 2b results for denifanstat in MASH and progress in acne and cancer programs.

Summary

• Sagimet Biosciences is developing denifanstat, a novel FASN inhibitor, for the treatment of MASH, acne, and cancer.
• Denifanstat targets the three key drivers of MASH: liver fat, inflammation, and fibrosis.
• The FASCINATE-2 Phase 2b trial in MASH met its primary endpoints, showing significant improvements in fibrosis without worsening of MASH.
• The study also showed enhanced treatment effects in patients with stable GLP-1 therapy.
• Denifanstat was generally well-tolerated in the study.
• Sagimet has a strategic collaboration with Ascletis for the development and commercialization of denifanstat in Greater China for acne and cancer.
• The company anticipates completing enrollment for the acne Phase 3 study by the end of 2024 and an interim analysis for the rGBM Phase 3 study by the end of 2024.
• Sagimet has $193.7 million in cash on hand as of March 31, 2024, which is expected to fund operations through 2025.
• A pivotal Phase 3 program for MASH is expected to begin in the second half of 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a strong financial position, indicating a high level of confidence in the company's future prospects. The manageable side effects and strategic collaborations further enhance the positive sentiment.

Positives

• Denifanstat demonstrated statistically significant improvements in fibrosis and MASH resolution in the Phase 2b trial.
• The drug showed a positive impact on advanced fibrosis in patients, including those with F3 fibrosis.
• Denifanstat was well-tolerated, with manageable side effects.
• The company has a strong cash position to fund operations through 2025.
• The drug has a unique mechanism of action that supports combination therapy.
• There is potential for precision medicine approaches using blood tests to identify responders to denifanstat.

Negatives

• Hair thinning was a notable adverse event, although it was manageable with dose adjustments.
• Some patients experienced serious adverse events, though the overall rate was low.
• The company is reliant on Ascletis for development and commercialization in Greater China.

Risks

• Clinical trial data may be subject to differing interpretations and assessments, including by regulatory authorities.
• Unfavorable new clinical trial data may emerge in other clinical trials of denifanstat, including Phase 3 trials.
• The company's relationship with Ascletis could impact the success of denifanstat development.
• The company's ability to maintain and successfully enforce adequate intellectual property protection is a risk.
• The company operates in a dynamic industry and economy, and new risk factors and uncertainties may emerge.

Future Outlook

The company expects to initiate a pivotal Phase 3 program for MASH in the second half of 2024 and anticipates completing enrollment for the acne Phase 3 study by the end of 2024. An interim analysis for the rGBM Phase 3 study is also planned for the second half of 2024. The company's cash on hand is expected to fund operations through 2025.

Management Comments

• Dave Happel, President & CEO, has over 20 years of experience in executive leadership in biotech and pharma.
• George Kemble, Executive Chairman, has over 20 years of experience in R&D in biotech and pharma.
• Eduardo Martins, CMO, has over 20 years of leadership of large-scale multinational clinical trials & global teams in pharma and biotech.
• Thierry Chauche, CFO, has over 20 years of financial and operational leadership experience in finance and healthcare companies.
• Elizabeth Rozek, General Counsel, has over 20 years of legal experience including executive leadership of legal, IP and compliance functions in biopharma and biotech.

Industry Context

The development of denifanstat is timely given the growing prevalence of MASH and the need for effective therapies. The company's focus on precision medicine and combination therapy aligns with current trends in drug development. The collaboration with Ascletis leverages their expertise in the Greater China market.

Comparison to Industry Standards

• The FASCINATE-2 trial results compare favorably to other MASH treatments in development, particularly in the improvement of fibrosis.
• The use of AI-based digital pathology for fibrosis assessment is an innovative approach.
• The focus on combination therapy aligns with the industry's move towards more comprehensive treatment strategies.
• The company's approach to precision medicine using blood tests is a novel approach to patient stratification.
• The development of a FASN inhibitor for acne and cancer is a unique approach compared to other companies in these spaces.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results and the company's financial stability.
• Employees may be motivated by the progress of the company's drug development programs.
• Patients with MASH, acne, and cancer may benefit from the development of new treatment options.
• Potential partners may be interested in collaborating with Sagimet on combination therapies or other development opportunities.

Next Steps

• Initiate a pivotal Phase 3 program for MASH in the second half of 2024.
• Complete enrollment for the acne Phase 3 study by the end of 2024.
• Conduct an interim analysis for the rGBM Phase 3 study by the end of 2024.
• Continue the development of tripalmitin and additional markers as potential biomarkers of treatment response.
• Advance preclinical combination studies with other MASH, diabetes, metabolism and obesity molecules.
• Pursue a Phase 2 trial in pediatric MASH following safety data compilation and nonclinical toxicology study.
• Continue translational work and patient selection strategy by bioinformatics on primary samples for cancer programs.
• Explore potential Phase 2 studies of FASN inhibitor in combination with marketed kinase inhibitors or KRAS inhibitors.

Key Dates

Keywords

Denifanstat, MASH, FASN inhibitor, Fibrosis, Acne, Cancer, Clinical trials, Liver disease, Metabolic dysfunction, Ascletis